Medtronic PLC $MDT Stock Holdings Lifted by Diversify Advisory Services LLC

Diversify Advisory Services LLC lifted its holdings in Medtronic PLC (NYSE:MDT - Free Report) by 12.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 109,132 shares of the medical technology company's stock after acquiring an additional 11,842 shares during the quarter. Diversify Advisory Services LLC's holdings in Medtronic were worth $10,417,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Gradient Investments LLC grew its holdings in shares of Medtronic by 3.9% during the second quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company's stock worth $38,842,000 after purchasing an additional 18,509 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in shares of Medtronic by 14.8% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 149,708 shares of the medical technology company's stock valued at $12,918,000 after buying an additional 19,315 shares in the last quarter. Czech National Bank raised its holdings in shares of Medtronic by 4.7% in the second quarter. Czech National Bank now owns 365,443 shares of the medical technology company's stock valued at $28,589,000 after buying an additional 16,292 shares during the last quarter. Worth Asset Management LLC acquired a new position in Medtronic during the 3rd quarter worth about $1,056,000. Finally, Congress Asset Management Co. acquired a new position in Medtronic during the 3rd quarter worth about $76,201,000. 82.06% of the stock is currently owned by institutional investors.

Insider Activity at Medtronic

In other Medtronic news, CEO Geoffrey Martha sold 50,000 shares of Medtronic stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the sale, the chief executive officer owned 277,866 shares of the company's stock, valued at approximately $26,397,270. The trade was a 15.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the company's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company's stock, valued at $3,950,718.90. The trade was a 3.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 61,903 shares of company stock worth $5,889,203 over the last ninety days. Company insiders own 0.27% of the company's stock.

Medtronic Stock Performance

Shares of NYSE:MDT opened at $94.56 on Wednesday. The stock has a market capitalization of $120.96 billion, a P/E ratio of 16.22, a P/E/G ratio of 2.17 and a beta of 0.55. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The business has a 50-day moving average price of $91.18 and a two-hundred day moving average price of $85.11.

Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company's revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts predict that Medtronic PLC will post 5.98 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.0%. The ex-dividend date was Friday, September 25th. Medtronic's dividend payout ratio is currently 70.94%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Weiss Ratings raised shares of Medtronic from a "hold (c+)" rating to a "buy (b-)" rating in a report on Monday. Piper Sandler reaffirmed a "neutral" rating on shares of Medtronic in a research note on Wednesday, October 14th. Barclays raised shares of Medtronic to a "hold" rating in a research note on Wednesday, October 7th. Wall Street Zen raised shares of Medtronic from a "hold" rating to a "buy" rating in a research note on Saturday, October 3rd. Finally, Robert W. Baird increased their price target on shares of Medtronic from $91.00 to $100.00 and gave the company a "neutral" rating in a research note on Wednesday, September 2nd. Eighteen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Medtronic has a consensus rating of "Moderate Buy" and an average price target of $102.88.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received the CE mark for its five-device Vitalis pacemaker portfolio. The devices use conduction system pacing to stimulate the heart’s natural electrical pathways, giving Medtronic a potential product and competitive-positioning opportunity in European markets. Medtronic’s next-gen pacemaker portfolio secures CE mark
• Positive Sentiment: The company appointed Michael Marinaro as president with an expanded role and completed the MiniMed spinoff. The changes could sharpen Medtronic’s strategic focus and allow management to concentrate more closely on its core medical-device businesses. Medtronic appoints new president and completes MiniMed spinoff
• Neutral Sentiment: Industry research projects continued growth in U.S. wireless cardiac monitoring, supported by reimbursement expansion, telehealth adoption and AI-enabled wearables. The trend is favorable for Medtronic’s cardiac portfolio, but the report does not announce new company-specific revenue or contracts. U.S. Wireless Cardiac Monitoring Systems Market Size, Share, and Forecast
• Neutral Sentiment: Recent trading commentary noted that MDT had underperformed during the prior session despite broader market gains. This reflects short-term market positioning rather than a new fundamental development. Medtronic Stock Dips While Market Gains: Key Facts
• Negative Sentiment: Medtronic insiders disclosed sizable stock sales, including an executive’s preplanned sale of 10,420 shares valued at roughly $1 million and a CEO sale reported at approximately $4.75 million. Because the transactions were planned, they may not signal deteriorating business prospects, but their size can weigh on sentiment. Medtronic Insider Sold Shares Worth $1,000,320
• Negative Sentiment: ETFs recorded approximately $94.9 million in net selling of MDT on October 16, indicating some passive or quantitative-fund pressure, though the impact may be temporary. Medtronic Sees $94.9 Million in Net ETF Selling

About Medtronic

Medtronic plc NYSE: MDT is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company's offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.